FDA raises safety questions on AstraZeneca's bleeding reversal agent

The FDA on Thursday will convene an advisory committee to discuss the safety and efficacy of AstraZeneca’s Andexxa, which won accelerated approval in 2018 to reverse the anticoagulation effects of blood thinners that can cause ...